Accutar Biotech Inc., a biotechnology company specializing in artificial intelligence (AI) – empowered drug discovery, today announced that Dr. Erika Hamilton, director of breast cancer research at Sarah Cannon Research Institute (SCRI), has joined the Scientific Advisory Board (“SAB”) of the company to advise on clinical trials of the company’s phase 1 breast cancer programs that are orally bioavailable, chimeric degrader molecules designed to target and degrade ERα protein with high potency and selectivity.
Dr. Hamilton is a leader in the field of both breast and gynecologic cancers. She had led numerous clinical trials, ranging from first-in-human phase I developmental trials to Phase III registrational trials. Her expertise led to her appointment as the chairperson of the ASCO Scientific Committee for Metastatic Breast Cancer, which is just one of her many recognitions and accomplishments. “We are honored to have Dr. Hamilton join our SAB at this critical inflection point for our company”, said Jie Fan, PhD, founder and CEO of Accutar. “Her innovative contributions to drug development, focus on advancing new therapies, and compassion for patients makes her the ideal person to help forge the next steps to bring our revolutionary medicine to patients.”
– Chimeric Degrader With a Differentiated Mechanism of Action vs. BTK Inhibitors by Removing Both Kinase And Scaffolding Functions of BTK –
– Broad BTK Mutant Coverage Designed to Overcome Resistance to Covalent And Non-Covalent BTK Inhibitors –
– Improved Selectivity Profile Sparing Common Off-Targets Observed for BTK Inhibitors –
CRANBURY, N.J.–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton’s Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage.
“The initiation of this study distinguishes Accutar as the first company to successfully bring oral chimeric degraders against three different targets into the clinic,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “Leveraging our protein crystallography and AI-empowered PPI-TAC (Protein-Protein Interaction Targeting Chimera) platforms, AC0676 was designed to potently and selectively degrade both wildtype BTK and BTK mutations that confer drug resistance to both covalent and non-covalent BTK inhibitors, including but not limited to C481S and kinase dead mutations such as L528W. We are excited about the differentiated therapeutic profile of AC0676 and its broad potential to treat patients with B-cell malignancies.”
The purpose of the Phase 1 multi-center, open-label study is to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0676 treatment in patients with relapsed/refractory B-cell malignancies, including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), , Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM). Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05780034).
About AC0676
AC0676 is an investigational orally bioavailable, chimeric degrader of Bruton’s Tyrosine Kinase (BTK) for the potential treatment of relapsed/refractory B-cell malignancies. In preclinical studies, AC0676 has demonstrated potent and selective BTK protein degradation with broad coverage of BTK wildtype and mutants (including C481S, L528W, and others), favorable pharmacological properties, as well as promising anti-tumor activity in animal models.
About Accutar Biotechnology, Inc.
Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.
Our Motto: Be transformative. For patients.
To learn more about Accutar, please visit us at www.accutarbio.com.
美国新泽西 & 中国上海–(BUSINESS WIRE)–(美国商业资讯)–冰洲石生物（Accutar Biotechnology, Inc.），一家专注于人工智能药物研发的临床阶段生物技术公司，今天宣布完成了AC0176在中国的1期临床研究第一例病人首次给药。这例病人在北京大学肿瘤医院入组并给药。
AC0176是由冰洲石生物自主研发并拥有全球专利的一种口服嵌合降解剂分子，可高效选择性地靶向降解雄激素受体蛋白。AC0176也成为全球范围内第一个获得FDA以及NMPA许可，进入临床试验的口服雄激素受体嵌合降解剂。
“这个临床一期标志着我们公司嵌合降解剂管线第二次进入中国临床试验。这是AC0176在去年启动美国1期临床研究和去年在中国IND获批之后的又一个里程碑。” 冰洲石生物首席执行官范捷博士说，“前列腺癌是中国男性中最常见的癌症之一，在中国发病率及死亡率增速均位列恶性肿瘤第一。我们期待中国I期临床研究极大地加速AC0176的研发，并进一步履行我们为全球癌症患者带来创新药物的承诺。” AC0176中国项目的主要研究者，来自北京大学肿瘤医院泌尿外科的杨勇主任及教授评价说:“本次临床试验的首例患者入组，也是国内首例作用于AR受体全新机制的蛋白降解药物的患者入组，标志着国内医学界在前列腺癌治疗领域迈出了重要一步，正在与国际接轨，对我们来说是一个振奋人心的里程碑，期待AC0176在临床中的表现，为中国患者家庭带来新的治疗希望。”
中国1期临床研究将评估AC0176治疗中国转移性去势抵抗性前列腺癌患者的安全性、耐受性、药代动力学和初步抗肿瘤活性。关于这个研究更多的信息列在www.clinicaltrials.gov网站 (NCT05673109).
关于 AC0176
AC0176是一种在研口服雄激素受体嵌合降解剂，用于治疗前列腺癌。雄激素受体是一种雄激素调节的转录因子，在前列腺癌的发生和增殖中起关键作用。在临床前研究中，AC0176证明了有效和选择性的雄激素受体蛋白降解，具有对多种雄激素受体突变有效的广谱性，良好的药理特性，以及在动物肿瘤模型中良好的抗肿瘤活性。
关于冰洲石生物（Accutar Biotechnology, Inc.）
Accutar 是一家临床阶段的生物技术公司，专注于人工智能支持的药物设计，尤其是临床差异化药物的研发。
变革治疗。心系患者。
欲了解有关Accutar的更多信息，请访问www.accutarbio.com。
CRANBURY, N.J. & SHANGHAI–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0176, an orally bioavailable chimeric degrader molecule designed to target Androgen Receptor (AR) protein with high potency and selectivity.
“The initiation of this study marks the second program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0176 Phase 1 study in the US and the IND clearance by the China National Medical Products Administration (NMPA) last year,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “Prostate cancer is one of the most common cancers among men in China, and the increase in its incidence and death ranks highest in China. We look forward to accelerating the development of AC0176 globally to bring transformative medicines to patients worldwide.”
The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0176 treatment in Chinese patients with metastatic Castration Resistant Prostate Cancer (mCRPC). Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05673109).
About AC0176
AC0176 is an investigational orally bioavailable, chimeric degrader of androgen receptor (AR) for the potential treatment of prostate cancers. AR is a hormonal transcription factor, and plays important roles during prostate cancer onset and progression. In preclinical studies, AC0176 has demonstrated potent and selective AR protein degradation with broad coverage of AR mutants, favorable pharmacological properties, as well as promising anti-tumor activities in animal models.
About Accutar Biotechnology, Inc.
Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.
Be transformative. For patients.
To learn more about Accutar, please visit us at www.accutarbio.com.
Responsibilities
Lead projects to develop theoretical model and computer assisted drug discovery
data/information system. Perform data mining in various medical/biological/chemical
data sources. Develop and test features and algorithms for organic synthesis of molecules.
Organize and lead structural biology-related experiment. Use public and in-house
experimental data to develop data-driven molecular force fields of higher accuracy to
improve its performance in tasks. Salary: $131,082
Requirements:
Bachelor degree in Biological Science or Biomedical Engineering required, and 5 years
of experience as Engineer or Researcher involving computer assisted drug discovery and
biological data mining required.
Send resume to HR, Accutar Biotechnology, Inc., 800 West El Camino Real, Suite 180,
Mountain View, CA 94040
Responsibilities
Develop modeling of complex biochemical molecules and other chemistry-related systems. Participate in the development and optimization of computer-assisted organic synthesis planning platform. Build and improve physical models of biomolecules, including docking models of small molecules into proteins, by data collection/interpretation and integration of physical/chemical knowledge into mathematical models. Perform data mining and analysis of drug discovery-related data/experiment results Lead and organize academic studies and tests, etc. Salary: $93,475
Requirements:
Master degree in Chemistry, Biochemistry, or Materials Chemistry required, and must have completed coursework in Dynamics, Quantum Mechanics, Computational Chemistry, and Ethical Chemical Research.
Send resume to HR, Accutar Biotechnology, Inc., 800 West El Camino Real, Suite 180, Mountain View, CA 94040
CRANBURY, N.J.–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0676 for the treatment of patients with relapsed/refractory B-cell malignancies. AC0676 is an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton’s Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage. BTK plays a crucial role in the B-cell receptor (BCR) signaling pathway, and its constitutive activation is essential to the pathophysiology of many B-cell malignancies. Accutar expects to begin enrollment of a Phase 1 clinical trial for AC0676 in the beginning of the second quarter of 2023.
“The IND clearance for AC0676 is another important validation that our protein crystallography and AI platforms can support and advance the discovery of potentially differentiated clinical candidates quickly, especially complex compounds such as chimeric degraders. It marks Accutar as the first company to successfully bring oral chimeric degraders against three different targets into clinics,” said Jie Fan, Ph.D., Chief Executive Officer, Accutar Biotechnology, Inc. “The IND clearance for AC0676 is also critical towards offering a potential new treatment option for B-cell malignancies based on a differentiated mechanism of action from covalent and non-covalent BTK inhibitors by removing both kinase and scaffolding functions of BTK. We look forward to the clinical benefit that AC0676 treatment can potentially provide to patients.”
The Phase 1 study will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0676 treatment in patients with relapsed/refractory B-cell malignancies.
About AC0676
AC0676 is an investigational orally bioavailable, chimeric degrader of Bruton’s Tyrosine Kinase (BTK) for the potential treatment of relapsed/refractory B-cell malignancies. In preclinical studies, AC0676 has demonstrated potent and selective BTK protein degradation with broad coverage of BTK wildtype and mutants (including C481S, L528W, and others), favorable pharmacological properties, as well as promising anti-tumor activities in animal models.
About Accutar Biotechnology, Inc.
Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.
Be transformative. For patients.
To learn more about Accutar, please visit us at www.accutarbio.com.
Design and develop drug discovery software and applications. Research and design novel
computer models to improve drug discovery pipeline. Implement, analyze, and optimize
the algorithms. Design and develop tools and platforms to improve productivity of the
team.
Send resume to HR, Accutar Biotechnology, Inc., 800 West El Camino Real, Suite 180,
Mountain View, CA 94040
美国新泽西 & 中国上海–(BUSINESS WIRE)–冰洲石生物（Accutar Biotechnology, Inc.），一家专注于人工智能药物研发的临床阶段生物技术公司，今天宣布完成了AC0682在中国的1期临床研究第一例病人首次给药。这例病人在北京大学肿瘤医院入组并给药。
AC0682是由冰洲石生物自主研发并拥有全球专利的一种口服嵌合降解剂分子，可高效选择性地靶向降解雌激素受体蛋白。AC0682也成为全球范围内第一个获得FDA以及NMPA许可，进入临床试验的口服雌激素受体嵌合降解剂。
“这个临床一期标志着我们公司嵌合降解剂管线第一次进入中国临床试验。这是AC0682在去年底获得美国IND批准并启动美国1期临床研究和今年在中国IND获批之后的又一个里程碑。” 冰洲石生物首席执行官范捷博士说，“乳腺癌是中国女性中最常见的癌症。我们期待中国I期临床研究极大地加速AC0682的研发，并进一步履行我们为全球癌症患者带来创新药物的承诺。” AC0682中国项目的组长单位北京大学肿瘤医院乳腺肿瘤内科的李惠平主任评价说:“能作为牵头人承接第一个在中国开展的作用于ER受体全新机制的蛋白降解药物，并完成了首例入组，标志着中国在药物临床研究进展方面已经与国际并行，势必推动新型药物的开发速度，使中国患者也能更早的用到被称为“蛋白降解先锋药物”的先进治疗方法。”
中国1期临床研究将评估AC0682治疗中国雌激素受体阳性乳腺癌患者的安全性、耐受性、药代动力学和初步抗肿瘤活性。关于这个研究更多的信息列在www.clinicaltrials.gov网站 (NCT05489679).
关于 AC0682
AC0682是一种在研口服雌激素受体嵌合降解剂，用于治疗雌激素受体阳性乳腺癌。雌激素受体是一种雌激素调节的转录因子，在乳腺癌的发生和增殖中起关键作用，近 80% 的乳腺癌表达雌激素受体。在临床前研究中，AC0682证明了有效和选择性的雌激素受体蛋白降解，具有良好的药理特性，以及在动物肿瘤模型中具有良好的抗肿瘤活性。
关于冰洲石生物（Accutar Biotechnology, Inc.）
Accutar 是一家临床阶段的生物技术公司，专注于人工智能支持的药物设计，尤其是临床差异化药物的研发。
变革治疗。心系患者。
欲了解有关Accutar的更多信息，请访问www.accutarbio.com。
CRANBURY, N.J. & SHANGHAI–(BUSINESS WIRE)–Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designed to target ERα protein with high potency and selectivity.
“The initiation of this study marks the first program from our chimeric degrader portfolio to enter the clinic in China, after the initiation of AC0682 Phase 1 study in the US late last year and the IND clearance by the China National Medical Products Administration (NMPA) earlier this year,” said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. “Breast cancer is the most common cancer type among Chinese women. We look forward to accelerating the development of AC0682 globally with the goal of bringing transformative medicines to patients worldwide.”
The Phase 1 study in China will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0682 treatment in Chinese patients with ER-positive breast cancer. Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05489679).
About AC0682
AC0682 is an investigational orally bioavailable, chimeric degrader of ERα for the potential treatment of ER-positive breast cancers. ERα is a hormone-regulated transcription factor that plays a critical role in breast cancer initiation and proliferation, and nearly 80% of breast cancers express ERα. In preclinical studies, AC0682 demonstrated potent and selective ERα protein degradation with favorable pharmacological properties, as well as promising anti-tumor activity in ER-positive animal tumor models.
About Accutar Biotechnology, Inc.
Accutar is a clinical stage biotech company focused on AI-empowered drug discovery, and its application to the discovery and development of clinically differentiated medicines.
Be transformative. For patients.
To learn more about Accutar, please visit us at www.accutarbio.com.